Alexion Pharmaceuticals (ALXN) 10-Q 25 Jul 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document	6 Months Ended
	Jun. 30, 2014	Jul. 23, 2014
Entity Information [Line Items]	'	'
Entity Registrant Name	'ALEXION PHARMACEUTICALS INC	'
Entity Central Index Key	'0000899866	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	197,814,997

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets	'	'
Cash and cash equivalents	$612,045	$529,857
Marketable securities	982,317	984,994
Trade accounts receivable, net	440,699	421,752
Inventories	144,859	102,602
Deferred tax assets	50,281	41,432
Prepaid expenses and other current assets	111,105	106,220
Total current assets	2,341,306	2,186,857
Property, plant and equipment, net	273,326	201,109
Intangible assets, net	599,786	609,719
Goodwill	254,073	254,073
Deferred tax assets	7,417	3,394
Other assets	77,902	62,544
Total assets	3,553,810	3,317,696
Liabilities and Stockholders' Equity	'	'
Accounts payable	36,066	21,596
Accrued expenses	204,743	402,344
Deferred revenue	72,271	53,801
Current portion of long-term debt	48,000	48,000
Other current liabilities	56,621	56,688
Total current liabilities	417,701	582,429
Long-term debt, less current portioon	33,500	65,000
Contingent consideration	108,232	106,744
Facility lease obligation	59,515	32,230
Deferred tax liabilities	96	101,241
Other liabilities	53,184	47,973
Total liabilities	672,228	935,617
Commitments and contingencies (Note 16)	'	'
Stockholders' Equity:	'	'
Preferred stock, $0.0001 par value; 5,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.0001 par value; 290,000 shares authorized; 200,035 and 197,941 shares issued at June 30, 2014 and December 31, 2013, respectively	20	20
Additional paid-in capital	2,467,945	2,106,183
Treasury stock, at cost, 2,134 and 985 shares at June 30, 2014 and December 31, 2013, respectively	-258,880	-80,365
Accumulated other comprehensive loss	-32,450	-22,857
Retained earnings	704,947	379,098
Total stockholders' equity	2,881,582	2,382,079
Total liabilities and stockholders' equity	$3,553,810	$3,317,696

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	290,000	290,000
Common stock, shares issued	200,035	197,941
Treasury Stock, Shares	2,134	985

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net product sales	$512,495	$370,091	$1,079,111	$709,032
Cost of sales	39,626	39,377	72,565	74,646
Operating expenses:	'	'	'	'
Research and development	92,554	68,563	284,011	143,099
Selling, general and administrative	159,477	123,189	288,768	232,015
Impairment of Intangible Asset	0	0	3,464	0
Acquisition-related costs	1,989	1,167	1,951	4,401
Amortization of purchased intangible assets	0	104	0	208
Total operating expenses	254,020	193,023	578,194	379,723
Operating income	218,849	137,691	428,352	254,663
Other income and expense:	'	'	'	'
Investment income	1,714	718	3,927	1,155
Interest expense	-715	-1,056	-1,778	-2,227
Foreign currency gain (loss)	-1,202	-90	56	413
Income before income taxes	218,646	137,263	430,557	254,004
Income tax provision	52,151	41,378	104,708	75,902
Net income	$166,495	$95,885	$325,849	$178,102
Earnings per common share	'	'	'	'
Basic	$0.84	$0.49	$1.65	$0.92
Diluted	$0.83	$0.48	$1.62	$0.90
Shares used in computing earnings per common share	'	'	'	'
Basic	197,880	195,247	197,838	193,944
Diluted	201,524	199,299	201,715	198,096

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income Statement (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net income	$166,495	$95,885	$325,849	$178,102
Other comprehensive income (loss), net of tax:	'	'	'	'
Foreign currency translation	46	-77	552	-1,529
Unrealized gains (losses) on marketable securities	299	-226	1,110	-226
Unrealized losses on pension obligation	-2,685	-2,684	-2,685	-2,684
Unrealized (losses) gains on hedging activities, net of tax of $(526), $(587), $(1,771) and $1,923, respectively	-3,675	-8,448	-8,570	17,330
Other comprehensive loss, net of tax	-6,015	-11,435	-9,593	12,891
Comprehensive income	$160,480	$84,450	$316,256	$190,993

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Unrealized gains (losses) on hedging activities - tax effect	($526)	($587)	($1,771)	$1,923

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net income	$325,849	$178,102
Adjustments to reconcile net income to net cash flows from operating activities:	'	'
Depreciation and amortization	19,042	13,014
Impairment of Intangible Asset	3,464	0
Change in fair value of contingent consideration	1,951	3,378
Share-based compensation expense	52,254	34,812
Premium amortization of available-for-sale securities	8,163	25
Deferred taxes	-112,425	25,985
Unrealized foreign currency gain	-4,046	-457
Unrealized loss (gain) on forward contracts	161	-561
Excess tax benefit from stock options	-254,547	-57,317
Other	148	23
Changes in operating assets and liabilities	'	'
Accounts receivable	-9,179	-55,178
Inventories	-34,972	-14,391
Prepaid expenses and other assets	-17,815	10,160
Accounts payable, accrued expenses and other liabilities	78,298	4,246
Deferred revenue	18,749	2,352
Net cash provided by operating activities	75,095	144,193
Cash flows from investing activities:	'	'
Purchases of available-for-sale securities	-278,134	-185,322
Proceeds from maturity or sale of available-for-sale securities	275,946	2,002
Purchases of trading securities	-1,765	0
Purchases of other investments	-25,000	0
Purchases of property, plant and equipment	-61,189	-14,012
Other	-26	207
Net cash used in investing activities	-90,116	-197,539
Cash flows from financing activities:	'	'
Payments on term loan	-31,500	-12,000
Excess tax benefit from stock options	254,547	57,317
Repurchase of common stock	-178,515	-66,136
Net proceeds from the exercise of stock options	52,181	23,577
Other	-81	-99
Net cash provided by financing activities	96,632	2,659
Effect of exchange rate changes on cash	577	-2,350
Net change in cash and cash equivalents	82,188	-53,037
Cash and cash equivalents at beginning of period	529,857	989,501
Cash and cash equivalents at end of period	612,045	936,464
Supplemental cash flow disclosures from investing and financing activities:	'	'
Construction in process related to facility lease obligation	$27,284	$6,854

Business

Business	6 Months Ended
	Jun. 30, 2014
Business [Abstract]	'
Business	'
	Business
	Alexion Pharmaceuticals, Inc. (Alexion, the Company, we, our or us) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Our marketed product Soliris is the first and only therapeutic approved for patients with either of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, and atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. We are also evaluating additional potential indications for Soliris in other severe and ultra-rare diseases in which uncontrolled complement activation is the underlying mechanism, and we are progressing in various stages of development with additional product candidates as potential treatments for patients with severe and life-threatening ultra-rare disorders.

Basis_of_Presentation_and_Prin

Basis of Presentation and Principles Of Consolidation	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation and Principles of Consolidation	'
	Basis of Presentation and Principles of Consolidation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. These accounting principles were applied on a basis consistent with those of the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2013. In our opinion, the accompanying unaudited consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States. The condensed consolidated balance sheet data as of December 31, 2013 was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2013 included in our Annual Report on Form 10-K. The results of operations for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the full year.
	The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss), net of tax, in stockholders' equity. Foreign currency transaction gains and losses are included in the results of operations in other income and expense.
	The accompanying unaudited condensed consolidated financial statements include the accounts of Alexion and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
	Our significant accounting policies are described in Note 1 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	New Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board issued a comprehensive new standard which amends revenue recognition principles and provides a single set of criteria for revenue recognition among all industries. The new standard provides a five step framework whereby revenue is recognized when promised goods or services are transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires enhanced disclosures pertaining to revenue recognition in both interim and annual periods. The standard is effective for interim and annual periods beginning after December 15, 2016 and allows for adoption using a full retrospective method, or a modified retrospective method. We are currently assessing the method of adoption and the expected impact the new standard has on our financial position and results of operations.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventory, Net [Abstract]	'
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or estimated realizable value. We determine the cost of inventory using the weighted-average cost method.
	The components of inventory are as follows:
		June 30,		December 31,
		2014		2013
	Raw materials	$	16,693	$	12,170
	Work-in-process	56,783		62,192
	Finished goods	71,383		28,240
		$	144,859	$	102,602
	As of June 30, 2014, we had capitalized $9,627 of inventory produced for commercial sale for products awaiting regulatory approval. At December 31, 2013, we did not have any inventory capitalized associated with such products.

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets and Goodwill	'
	Intangible Assets and Goodwill
	The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization:
		June 30, 2014		December 31, 2013
	Licenses, patents and purchased technology, net	$	4,736	$	11,205
	Acquired in-process research and development	595,050		598,514
	Intangible assets	$	599,786	$	609,719
	Goodwill	$	254,073	$	254,073
	During first quarter of 2014, we reviewed for impairment the value of an early stage, Phase I indefinite-lived intangible asset related to the Taligen acquisition. We initiated such review based on a reassessment of scientific findings associated with this acquired asset. As a result, during the six months ended June 30, 2014, we recognized an impairment of $3,464 to adjust this asset to fair value, which was determined to be de minimis.

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt [Abstract]	'
Debt	'
	Debt
	On February 7, 2012, we entered into a Credit Agreement with a syndicate of banks that provides for a $240,000 senior secured term loan facility payable in equal quarterly installments of $12,000 starting June 30, 2012 and a $200,000 senior secured revolving credit facility through February 7, 2017. In addition to borrowings upon prior notice, the revolving credit facility includes borrowing capacity in the form of letters of credit up to $60,000 and borrowings on same-day notice, referred to as swingline loans, of up to $10,000. Borrowings can be used for working capital requirements, acquisitions and other general corporate purposes. With the consent of the lenders and the administrative agent and subject to satisfaction of certain conditions, we may increase the term loan facility and/or the revolving credit facility by an aggregate amount not to exceed $150,000.
	As of June 30, 2014, we had $81,500 outstanding on the term loan. As of June 30, 2014, we had open letters of credit of $12,445, and our borrowing availability under the revolving facility was $187,555.
	The fair value of our long term debt, which is measured using Level 2 inputs, approximates book value.

Earnings_Per_Common_Share

Earnings Per Common Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Common Share [Abstract]	'
Earnings Per Common Share	'
	Earnings Per Common Share
	Basic earnings per common share (EPS) is computed by dividing net income by the weighted-average number of shares of common stock outstanding. For purposes of calculating diluted EPS, the denominator reflects the potential dilution that could occur if stock options, unvested restricted stock, unvested restricted stock units or other contracts to issue common stock were exercised or converted into common stock, using the treasury stock method.
	The following table summarizes the calculation of basic and diluted EPS for the three and six months ended June 30, 2014 and 2013:
		Three months ended				Six months ended
		June 30,				June 30,
		2014		2013		2014		2013
	Net income used for basic and diluted calculation	$	166,495	$	95,885	$	325,849	$	178,102
	Shares used in computing earnings per common share—basic	197,880		195,247		197,838		193,944
	Weighted-average effect of dilutive securities:
	Stock awards	3,644		4,052		3,877		4,152
	Dilutive potential common shares	3,644		4,052		3,877		4,152
	Shares used in computing earnings per common share—diluted	201,524		199,299		201,715		198,096
	Earnings per common share:
	Basic	$	0.84	$	0.49	$	1.65	$	0.92
	Diluted	$	0.83	$	0.48	$	1.62	$	0.9
	We exclude from EPS the weighted-average number of securities whose effect is anti-dilutive. Excluded from the calculation of EPS for the three and six months ended June 30, 2014 were 1,698 and 1,151 shares of common stock, respectively, because their effect is anti-dilutive. Similarly, we excluded 2,265 and 3,037 shares from the calculation of EPS for the three and six months ended June 30, 2013, respectively, because their effect was anti-dilutive.

Marketable_Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Marketable securities	'
	Marketable Securities
	The amortized cost, gross unrealized holding gains, gross unrealized holding losses and estimated fair value of available-for-sale investments by type of security at June 30, 2014 and December 31, 2013 were as follows:
			30-Jun-14
			Amortized Cost				Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Estimated Fair Value
	Commercial paper		$	66,448			$	—	$	—		$	66,448
	Corporate bonds		484,588				916		(120		)	485,384
	Municipal bonds		207,643				251		—			207,894
	Other government-related obligations:
	U.S.		51,969				37		(21		)	51,985
	Foreign		149,573				208		(41		)	149,740
	Bank certificates of deposit		18,004				5		—			18,009
			$	978,225			$	1,417	$	(182	)	$	979,460
			December 31, 2013
			Amortized Cost Basis				Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Aggregate Fair Value
	Commercial paper		$	112,679			$	—	$	—		$	112,679
	Corporate bonds		476,459				487		(588		)	476,358
	Municipal bonds		202,396				47		(40		)	202,403
	Other government-related obligations:
	U.S.		46,466				30		(7		)	46,489
	Foreign		156,974				54		(204		)	156,824
	Bank certificates of deposit		33,004				—		—			33,004
			$	1,027,978			$	618	$	(839	)	$	1,027,757
	The aggregate fair value of available-for-sale securities in an unrealized loss position as of June 30, 2014 and December 31, 2013 was $210,079 and $461,634, respectively. Investments that have been in a continuous unrealized loss position for more than 12 months are not material. As of June 30, 2014, we believe that the cost basis of our available-for-sale investments is recoverable.
	The fair values of available-for-sale securities by classification in the condensed consolidated balance sheet were as follows:
		June 30, 2014			December 31, 2013
	Cash and cash equivalents	$	—		$	43,780
	Marketable securities	979,460			983,977
		$	979,460		$	1,027,757
	The fair values of available-for-sale debt securities at June 30, 2014, by contractual maturity, are summarized as follows:
		June 30, 2014
	Due in one year or less	$	417,471
	Due after one year through three years	561,989
	Due after three years through five years	—
		$	979,460
	As of June 30, 2014 and December 31, 2013, the fair value of our trading securities was $2,857 and $1,017, respectively.
	We utilize the specific identification method in computing realized gains and losses. Realized gains and losses on our trading securities and available-for-sale investments were not material for the three and six months ended June 30, 2014 and 2013.

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Activities	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities [Abstract]	'
Derivative Instruments and Hedging Activities	'
	Derivative Instruments and Hedging Activities
	We operate internationally and, in the normal course of business, are exposed to fluctuations in foreign currency exchange rates. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, primarily the Euro, Japanese Yen, and British Pound. We manage our foreign currency transaction risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.
	We enter into foreign exchange forward contracts, with durations of up to 36 months, to hedge exposures resulting from portions of our forecasted revenues, including intercompany revenues, that are denominated in currencies other than the U.S. dollar. The purpose of the hedges of revenue is to reduce the volatility of exchange rate fluctuations on our operating results and to increase the visibility of the foreign exchange impact on forecasted revenues. These hedges are designated as cash flow hedges upon contract inception. At June 30, 2014, we had open contracts with notional amounts totaling $1,410,389 that qualified for hedge accounting.
	The impact on accumulated other comprehensive income (AOCI) and earnings from foreign exchange contracts that qualified as cash flow hedges, for the three and six months ended June 30, 2014 and 2013 were as follows:
		Three months ended							Six months ended
		June 30,							June 30,
		2014				2013			2014				2013
	Gain (loss) recognized in AOCI, net of tax	$	(4,119	)		$	(1,388	)	$	(8,063	)		$	29,537
	Gain (loss) reclassified from AOCI to net product sales (effective portion), net of tax	$	(608	)		$	6,864		$	500			$	11,579
	Gain reclassified from AOCI to other income and expense (ineffective portion), net of tax	$	164			$	196		$	7			$	628
	Assuming no change in foreign exchange rates from market rates at June 30, 2014, $7,000 of losses recognized in AOCI will be reclassified to revenue over the next 12 months.
	We enter into foreign exchange forward contracts, with durations of approximately 30 days, designed to limit the balance sheet exposure of monetary assets and liabilities. We enter into these hedges to reduce the impact of fluctuating exchange rates on our operating results. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of June 30, 2014, the notional amount of foreign exchange contracts where hedge accounting is not applied was $239,318.
	We recognized a gain (loss) of $(1,640) and $1,837, in other income and expense, for the three months ended June 30, 2014 and 2013, respectively, and $649 and $8,787, for the six months ended June 30, 2014 and 2013, respectively, associated with the foreign exchange contracts not designated as hedging instruments. These amounts were largely offset by gains or losses in monetary assets and liabilities.
	The following tables summarize the fair value of outstanding derivatives at June 30, 2014 and December 31, 2013:
		June 30, 2014
		Asset Derivatives						Liability Derivatives
		Balance Sheet		Fair				Balance Sheet	Fair
		Location		Value				Location	Value
	Derivatives designated as hedging instruments:
	Foreign exchange forward contracts	Other current assets		$	13,018			Other current liabilities	$	19,729
	Foreign exchange forward contracts	Other non-current assets		4,115				Other non-current liabilities	11,285
	Total fair value of derivative instruments			$	17,133				$	31,014
		December 31, 2013
		Asset Derivatives						Liability Derivatives
		Balance Sheet		Fair				Balance Sheet	Fair
		Location		Value				Location	Value
	Derivatives designated as hedging instruments:
	Foreign exchange forward contracts	Other current assets		$	21,815			Other current liabilities	$	20,228
	Foreign exchange forward contracts	Other non-current assets		9,839				Other non-current liabilities	14,864
	Total fair value of derivative instruments			$	31,654				$	35,092
	The fair value of our foreign exchange forward contracts that are not designated as hedging instruments was zero as of June 30, 2014 and December 31, 2013.
	Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association (ISDA) agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following table summarizes the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts subject to such provisions:
			30-Jun-14
														Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
	Description		Gross Amounts of Recognized Assets/Liabilities				Gross Amounts Offset in the Condensed Consolidated Balance Sheet			Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet				Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
	Derivative assets		$	17,133			$	—		$	17,133			$	(15,934	)	$	—	$	1,199
	Derivative liabilities		(31,014		)		—			(31,014		)		15,934			—		(15,080		)
			December 31, 2013
														Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
	Description		Gross Amounts of Recognized Assets/Liabilities				Gross Amounts Offset in the Condensed Consolidated Balance Sheet			Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet				Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
	Derivative assets		$	31,654			$	—		$	31,654			$	(27,256	)	$	—	$	4,398
	Derivative liabilities		(35,092		)		—			(35,092		)		27,256			—		(7,836		)

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	Stockholders' Equity
	In November 2012, our Board of Directors authorized the repurchase of up to $400,000 of our common stock. This repurchase program does not have an expiration date, and we are not obligated to acquire a particular number of shares. The program may be discontinued at any time at the Company's discretion. Under the program, we repurchased 1,012 and 353 shares of our common stock at a cost of $156,458 and $31,029 during the three months ended June 30, 2014 and 2013, respectively, and 1,149 and 758 shares of our common stock at a cost of $178,515 and $66,136 during the six months ended June 30, 2014 and 2013, respectively. As of June 30, 2014, there is a total of $143,796 remaining for repurchases under the program.
	Subsequent to June 30, 2014, we repurchased 180 shares of our common stock under our repurchase program at a cost of $28,968.

Other_Comprehensive_Income_and

Other Comprehensive Income and Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Income [Abstract]	'
Other Comprehensive Income and Accumulated Other Comprehensive Income	'
	Other Comprehensive Income and Accumulated Other Comprehensive Income
	The following tables summarize the changes in AOCI, by component, for the six months ended June 30, 2014 and 2013:
		Defined Benefit Pension Plans				Unrealized Gains (Losses) from Marketable Securities			Unrealized Gains (Losses) from Hedging Activities				Foreign Currency Translation Adjustment				Total Accumulated Other Comprehensive Income (Loss)
	Balances, December 31, 2013	$	(11,502	)		$	(146	)	$	(3,827	)		$	(7,382	)		$	(22,857	)
	Other comprehensive income before reclassifications	(3,086		)		1,111			(8,063		)		552				(9,486		)
	Amounts reclassified from other comprehensive income	401				(1		)	(507		)		—				(107		)
	Net other comprehensive income (loss)	(2,685		)		1,110			(8,570		)		552				(9,593		)
	Balances, June 30, 2014	$	(14,187	)		$	964		$	(12,397	)		$	(6,830	)		$	(32,450	)
		Defined Benefit Pension Plans				Unrealized Gains (Losses) from Marketable Securities			Unrealized Gains (Losses) from Hedging Activities				Foreign Currency Translation Adjustment				Total Accumulated Other Comprehensive Income (Loss)
	Balances, December 31, 2012	$	(5,712	)		$	—		$	15,156			$	(2,809	)		$	6,635
	Other comprehensive income before reclassifications	(2,873		)		(225		)	29,537				(1,529		)		24,910
	Amounts reclassified from other comprehensive income	189				(1		)	(12,207		)		—				(12,019		)
	Net other comprehensive income (loss)	(2,684		)		(226		)	17,330				(1,529		)		12,891
	Balances, June 30, 2013	$	(8,396	)		$	(226	)	$	32,486			$	(4,338	)		$	19,526
	The table below provides details regarding significant reclassifications from AOCI during the three and six months ended June 30, 2014 and 2013:
	Details about Accumulated Other Comprehensive Income Components		Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended June 30,						Amount Reclassified From Accumulated Other Comprehensive Income during the six months ended June 30,							Affected Line Item in the Condensed Consolidated Statements of Operations
			2014			2013			2014			2013
	Unrealized Gains (Losses) from Hedging Activity
	Effective portion of foreign exchange contracts		$	(695	)	$	7,502		$	571		$	12,655			Net product sales
	Ineffective portion of foreign exchange contracts		187			214			8			686				Foreign currency gain (loss)
			(508		)	7,716			579			13,341
			64			(656		)	(72		)	(1,134		)		Income tax provision
			$	(444	)	$	7,060		$	507		$	12,207
	Unrealized Gains (Losses) from Marketable Securities
	Realized gains (losses) on sale of securities		$	—		$	2		$	2		$	2			Investment income
			—			2			2			2
			—			(1		)	(1		)	(1		)		Income tax provision
			$	—		$	1		$	1		$	1
	Defined Benefit Pension Plans
	Amortization of prior service costs and actuarial losses		$	(359	)	$	(131	)	$	(438	)	$	(207	)		(a)
			(359		)	(131		)	(438		)	(207		)
			31			11			37			18				Income tax provision
			$	(328	)	$	(120	)	$	(401	)	$	(189	)
	(a) This AOCI component is included in the computation of net periodic pension benefit cost (see Note 13 for additional details).

Fair_Value_Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurement	'
	Fair Value Measurement
	Authoritative guidance establishes a valuation hierarchy for disclosure of the inputs to the valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.
	The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.
			Fair Value Measurement at
			30-Jun-14
	Balance Sheet	Type of Instrument	Total		Level 1		Level 2		Level 3
	Classification
	Cash equivalents	Institutional money market funds	$	256,300	$	—	$	256,300	$	—
	Marketable securities	Mutual funds	$	2,857	$	2,857	$	—	$	—
	Marketable securities	Commercial paper	$	66,448	$	—	$	66,448	$	—
	Marketable securities	Corporate bonds	$	485,384	$	—	$	485,384	$	—
	Marketable securities	Municipal bonds	$	207,894	$	—	$	207,894	$	—
	Marketable securities	Other government-related obligations	$	201,725	$	—	$	201,725	$	—
	Marketable securities	Bank certificates of deposit	$	18,009	$	—	$	18,009	$	—
	Other current assets	Foreign exchange forward contracts	$	13,018	$	—	$	13,018	$	—
	Other assets	Foreign exchange forward contracts	$	4,115	$	—	$	4,115	$	—
	Other current liabilities	Foreign exchange forward contracts	$	19,729	$	—	$	19,729	$	—
	Other liabilities	Foreign exchange forward contracts	$	11,285	$	—	$	11,285	$	—
	Other current liabilities	Acquisition-related contingent consideration	$	36,395	$	—	$	—	$	36,395
	Contingent consideration	Acquisition-related contingent consideration	$	108,232	$	—	$	—	$	108,232
			Fair Value Measurement at
			31-Dec-13
	Balance Sheet	Type of Instrument	Total		Level 1		Level 2		Level 3
	Classification
	Cash equivalents	Institutional money market funds	$	234,212	$	—	$	234,212	$	—
	Cash equivalents	Commercial paper	$	6,298	$	—	$	6,298	$	—
	Cash equivalents	Corporate bonds	$	15,255	$	—	$	15,255	$	—
	Cash equivalents	Municipal bonds	$	2,225	$	—	$	2,225	$	—
	Cash equivalents	Bank certificates of deposit	$	20,003	$	—	$	20,003	$	—
	Marketable securities	Mutual funds	$	1,017	$	1,017	$	—	$	—
	Marketable securities	Commercial paper	$	106,381	$	—	$	106,381	$	—
	Marketable securities	Corporate bonds	$	461,103	$	—	$	461,103	$	—
	Marketable securities	Municipal bonds	$	200,178	$	—	$	200,178	$	—
	Marketable securities	Other government-related obligations	$	203,313	$	—	$	203,313	$	—
	Marketable securities	Bank certificates of deposit	$	13,001	$	—	$	13,001	$	—
	Other current assets	Foreign exchange forward contracts	$	21,815	$	—	$	21,815	$	—
	Other assets	Foreign exchange forward contracts	$	9,839	$	—	$	9,839	$	—
	Other current liabilities	Foreign exchange forward contracts	$	20,228	$	—	$	20,228	$	—
	Other liabilities	Foreign exchange forward contracts	$	14,864	$	—	$	14,864	$	—
	Other current liabilities	Acquisition-related contingent consideration	$	35,932	$	—	$	—	$	35,932
	Contingent consideration	Acquisition-related contingent consideration	$	106,744	$	—	$	—	$	106,744
	There were no securities transferred between Level 1, 2 and 3 during the six months ended June 30, 2014.
	Valuation Techniques
	We classify mutual fund investments, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.
	Cash equivalents and marketable securities classified as Level 2 within the valuation hierarchy consist of institutional money market funds, commercial paper, municipal bonds, U.S. and foreign government-related debt, corporate debt securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.
	Our derivative assets and liabilities include foreign exchange derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk, as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the valuation hierarchy.
	Contingent consideration liabilities related to acquisitions are classified as Level 3 within the valuation hierarchy and are valued based on various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are met.
	As of June 30, 2014, there has not been any impact to the fair value of our derivative liabilities due to our own credit risk. Similarly, there has not been any significant adverse impact to our derivative assets based on our evaluation of our counterparties’ credit risks.
	Contingent Consideration
	In connection with prior acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We determine the fair value of these obligations on the acquisition date using various estimates that are not observable in the market and represent a Level 3 measurement within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a cost of debt ranging from 5.3% to 6.2% for developmental milestones and a weighted average cost of capital ranging from 14% to 21% for sales-based milestones.
	Each reporting period, we adjust the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time as development work progresses towards the achievement of the milestones.
	Estimated future contingent milestone payments related to prior business combinations range from zero if no milestone events are achieved, to a maximum of $876,000 if all development, regulatory and sales-based milestones are reached. As of June 30, 2014, the fair value of acquisition-related contingent consideration was $144,627. The following table represents a roll-forward of our acquisition-related contingent consideration:
		Six months ended
		30-Jun-14
	Balance at beginning of period	$	(142,676	)
	Changes in fair value	(1,951		)
	Balance at end of period	$	(144,627	)

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The following table provides a comparative summary of our income tax provision and effective tax rate for the three and six months ended June 30, 2014 and 2013:
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Provision for income taxes	$	52,151		$	41,378		$	104,708		$	75,902
	Effective tax rate	23.9		%	30.1		%	24.3		%	29.9		%
	The tax provision for the three and six months ended June 30, 2014 is attributable to the U.S. federal, state and foreign income taxes on our operations. Additionally, included in the six months ended June 30, 2014 is $2,128 of tax attributable to our agreement with the French government that provided reimbursement for shipments of Soliris made prior to January 1, 2014. The tax provision for the three and six months ended June 30, 2013 is attributable to the U.S. federal, state and foreign income taxes on our operations. Additionally, included in the six months ended June 30, 2013 is a benefit of $3,033 attributable to the 2012 U.S. Federal tax credit for research and experimentation. The reduction in the effective tax rate for the three and six months ended June 30, 2014 as compared to the same periods in the prior year is primarily attributable to the centralization of our global supply chain and technical operations in Ireland.
	The U.S. Federal tax credit for research and experimentation expenses expired December 31, 2011.  In connection with this expiration, our 2012 tax expense did not include any benefit from the U.S. Federal tax credit for research and experimentation.  In January 2013, the American Taxpayer Relief Act of 2012, which retroactively extended the tax credit for research and experimentation back to January 1, 2012 through the end of 2013, was signed into law.  The effects of a change in tax law is recognized in the period that includes the date of enactment and, therefore, our tax benefit attributable to the 2012 U.S. Federal tax credit for research and experimentation was recorded in the first quarter of 2013.
	The U.S. Federal tax credit for research and experimentation expenses expired again on December 31, 2013. In connection with this expiration, our 2014 tax provision does not include any benefit from the U.S. Federal tax credit for research and experimentation.
	We continue to maintain a valuation allowance against certain other deferred tax assets where realization is not certain.

Employee_Benefit_Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
Employee Benefit Plans	'
	Employee Benefit Plans
	Deferred Compensation Plan
	Effective June 15, 2013, we began sponsoring a nonqualified deferred compensation plan which allows certain highly-compensated employees to make voluntary deferrals of up to 80% of their base salary and incentive bonuses. The plan is designed to work in conjunction with the 401(k) plan and provides for a total combined employer match of up to 6% of an employee's eligible earnings, up to the IRS annual 401(k) contribution limitations. Employee deferrals and employer matching contributions under the plan began in the third quarter of 2013. Matching contributions were not material for the three and six months ended June 30, 2014. As of June 30, 2014 and December 31, 2013, we recorded a liability of $2,857 and $1,097 associated with our nonqualified deferred compensation plan. We invest employee deferrals and employer matching contributions in mutual fund investments. These investments, which are recorded at the same value as the liability, are classified as trading securities and are included in marketable securities in our condensed consolidated balance sheet.
	Defined Contribution Plan
	We have one qualified 401(k) plan covering all eligible employees. Under the plan, employees may contribute up to the statutory allowable amount for any calendar year. We make matching contributions equal to $1.00 for each dollar contributed up to the first 6% of an individual's base salary and incentive cash bonus. For the three months ended June 30, 2014 and 2013, we recorded matching contributions of approximately $2,279, and $1,497, respectively. For the six months ended June 30, 2014 and 2013, we recorded matching contributions of approximately $4,936 and $3,264, respectively.
	Defined Benefit Plans
	We maintain defined benefit plans for employees in certain countries outside the United States, including retirement benefit plans required by applicable local law. The plans are valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increases, and pension adjustments.
	The components of net periodic benefit cost were as follows:
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Service cost	$	2,622		$	1,326		$	4,185		$	2,711
	Interest cost	200			123			400			249
	Expected return on plan assets	(232		)	(156		)	(463		)	(314		)
	Employee contributions	(482		)	(358		)	(877		)	(713		)
	Amortization	359			131			438			207
	Total net periodic benefit cost	$	2,467		$	1,066		$	3,683		$	2,140

Leases

Leases	6 Months Ended
	Jun. 30, 2014
Leases [Abstract]	'
Leases	'
	Leases
	In November 2012, we entered into a lease agreement for office and laboratory space to be constructed in New Haven, Connecticut. Although we will not legally own the premises, we are deemed to be the owner of the building during the construction period based on applicable accounting guidance for build-to-suit leases due to our involvement during the construction period. Accordingly, the landlord's costs of constructing the facility are required to be capitalized, as a non-cash transaction, offset by a corresponding facility lease obligation in our condensed consolidated balance sheet.
	Construction of the new facility began in June 2013 and is expected to be completed in 2015. As of June 30, 2014, we recorded a construction-in-process asset of $62,157, inclusive of the landlord's costs as well as costs incurred by Alexion, and an offsetting facility lease obligation of $59,515 associated with the new facility.

License_Agreements_Notes

License Agreements (Notes)	6 Months Ended
	Jun. 30, 2014
Research and Development [Abstract]	'
License Agreements	'
	License Agreements
	In January 2014, we entered into an agreement with Moderna Therapeutics, Inc. (Moderna) that allows us to purchase ten product options to develop and commercialize treatments for rare diseases with Moderna's messenger RNA (mRNA) therapeutics platform. Alexion will lead the discovery, development and commercialization of the treatments produced through this broad, long-term strategic agreement, while Moderna will retain responsibility for the design and manufacture of the messenger RNA against selected targets. Due to the early stage of these assets, we recorded expense for an upfront payment of $100,000.  We will also be responsible for funding research activities under the program.  In addition, for each drug target, up to a maximum of ten targets, we could be required to make an option exercise payment of $15,000 and to pay up to an additional $120,000 with respect to a rare disease product and $400,000 with respect to a non-rare disease product in development and sales milestones if the specific milestones are met over time as well as royalties on commercial sales.
	In addition to the option agreement, we purchased $25,000 of non-voting preferred equity of Moderna LLC, Moderna's non-public parent company. We recorded this investment at cost within other assets in our condensed consolidated balance sheets. We regularly monitor the investment to evaluate whether there has been an other-than-temporary decline in its fair value, based on the implied value of recent company financings, public market prices of comparable companies, and general market conditions. The carrying value of this investment was not impaired as of June 30, 2014.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Commitments
	Lonza Agreement
	We have supply agreements with Lonza Group AG and its affiliates (Lonza), a third party manufacturer, relating to the manufacture of Soliris and asfotase alfa. We have various agreements with Lonza, with remaining total commitments of approximately $146,000 through 2018. Such commitments may be canceled only in limited circumstances. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of Soliris manufactured at Alexion Rhode Island Manufacturing Facility (ARIMF).
	Contingent Liabilities
	We are currently involved in various claims, lawsuits and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on our best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, we may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustment to our operating results.
	In March 2013, we received a Warning Letter from the U.S. Food and Drug Administration (FDA) regarding compliance with current Good Manufacturing Practices at ARIMF. The Warning Letter followed an FDA inspection which concluded in August 2012. At the conclusion of that inspection, the FDA issued a Form 483 Inspectional Observations, to which we responded in August 2012 and provided additional information to the FDA in September and December 2012. The observations relate to commercial and clinical manufacture of Soliris at ARIMF. We responded to the Warning Letter in a letter to the FDA in April 2013. We continue to manufacture products, including Soliris, in this facility. In the first quarter of 2014, we submitted our request for inspection to the FDA, and we are currently awaiting this re-inspection of ARIMF. While the resolution of this Warning Letter is difficult to predict, we do not currently believe a loss related to this matter is probable or that the potential magnitude of such loss or range of loss, if any, can be reasonably estimated.
	In 2013 and 2014, we initiated voluntary recalls and replacements of certain lots of Soliris due to the presence of visible particles detected in a limited number of vials in these lots. These recalls did not interrupt the supply of Soliris to patients. Following investigation, we believe that we have identified the filling process step that resulted in the presence of the visible particles and we have implemented the changes necessary to modify the process step. During the fourth quarter of 2013, we recorded expense of $14,277 in cost of sales resulting from the expected disposal of inventory in 2014, and we do not expect a material impact from these recalls in 2014.

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory, Net [Abstract]	'
Schedule of Inventory, Current	'
	The components of inventory are as follows:
		June 30,		December 31,
		2014		2013
	Raw materials	$	16,693	$	12,170
	Work-in-process	56,783		62,192
	Finished goods	71,383		28,240
		$	144,859	$	102,602

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets and Goodwill	'
	The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization:
		June 30, 2014		December 31, 2013
	Licenses, patents and purchased technology, net	$	4,736	$	11,205
	Acquired in-process research and development	595,050		598,514
	Intangible assets	$	599,786	$	609,719
	Goodwill	$	254,073	$	254,073

Earnings_Per_Common_Share_Tabl

Earnings Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Common Share [Abstract]	'
Schedule Of Basic And Diluted Earnings Per Share	'
	The following table summarizes the calculation of basic and diluted EPS for the three and six months ended June 30, 2014 and 2013:
		Three months ended				Six months ended
		June 30,				June 30,
		2014		2013		2014		2013
	Net income used for basic and diluted calculation	$	166,495	$	95,885	$	325,849	$	178,102
	Shares used in computing earnings per common share—basic	197,880		195,247		197,838		193,944
	Weighted-average effect of dilutive securities:
	Stock awards	3,644		4,052		3,877		4,152
	Dilutive potential common shares	3,644		4,052		3,877		4,152
	Shares used in computing earnings per common share—diluted	201,524		199,299		201,715		198,096
	Earnings per common share:
	Basic	$	0.84	$	0.49	$	1.65	$	0.92
	Diluted	$	0.83	$	0.48	$	1.62	$	0.9

Marketable_Securities_Tables

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	'
	The amortized cost, gross unrealized holding gains, gross unrealized holding losses and estimated fair value of available-for-sale investments by type of security at June 30, 2014 and December 31, 2013 were as follows:
			30-Jun-14
			Amortized Cost				Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Estimated Fair Value
	Commercial paper		$	66,448			$	—	$	—		$	66,448
	Corporate bonds		484,588				916		(120		)	485,384
	Municipal bonds		207,643				251		—			207,894
	Other government-related obligations:
	U.S.		51,969				37		(21		)	51,985
	Foreign		149,573				208		(41		)	149,740
	Bank certificates of deposit		18,004				5		—			18,009
			$	978,225			$	1,417	$	(182	)	$	979,460
			December 31, 2013
			Amortized Cost Basis				Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Aggregate Fair Value
	Commercial paper		$	112,679			$	—	$	—		$	112,679
	Corporate bonds		476,459				487		(588		)	476,358
	Municipal bonds		202,396				47		(40		)	202,403
	Other government-related obligations:
	U.S.		46,466				30		(7		)	46,489
	Foreign		156,974				54		(204		)	156,824
	Bank certificates of deposit		33,004				—		—			33,004
			$	1,027,978			$	618	$	(839	)	$	1,027,757
Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block]	'
	The fair values of available-for-sale securities by classification in the condensed consolidated balance sheet were as follows:
		June 30, 2014			December 31, 2013
	Cash and cash equivalents	$	—		$	43,780
	Marketable securities	979,460			983,977
		$	979,460		$	1,027,757
Investments Classified by Contractual Maturity Date [Table Text Block]	'
	The fair values of available-for-sale debt securities at June 30, 2014, by contractual maturity, are summarized as follows:
		June 30, 2014
	Due in one year or less	$	417,471
	Due after one year through three years	561,989
	Due after three years through five years	—
		$	979,460

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Activities (Tables)	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities [Abstract]	'
Schedule of Other Comprehensive Income and Earnings from Foreign Exchange Contracts	'
	The impact on accumulated other comprehensive income (AOCI) and earnings from foreign exchange contracts that qualified as cash flow hedges, for the three and six months ended June 30, 2014 and 2013 were as follows:
		Three months ended							Six months ended
		June 30,							June 30,
		2014				2013			2014				2013
	Gain (loss) recognized in AOCI, net of tax	$	(4,119	)		$	(1,388	)	$	(8,063	)		$	29,537
	Gain (loss) reclassified from AOCI to net product sales (effective portion), net of tax	$	(608	)		$	6,864		$	500			$	11,579
	Gain reclassified from AOCI to other income and expense (ineffective portion), net of tax	$	164			$	196		$	7			$	628
Schedule of Fair Value of Outstanding Derivatives	'
	The following tables summarize the fair value of outstanding derivatives at June 30, 2014 and December 31, 2013:
		June 30, 2014
		Asset Derivatives						Liability Derivatives
		Balance Sheet		Fair				Balance Sheet	Fair
		Location		Value				Location	Value
	Derivatives designated as hedging instruments:
	Foreign exchange forward contracts	Other current assets		$	13,018			Other current liabilities	$	19,729
	Foreign exchange forward contracts	Other non-current assets		4,115				Other non-current liabilities	11,285
	Total fair value of derivative instruments			$	17,133				$	31,014
		December 31, 2013
		Asset Derivatives						Liability Derivatives
		Balance Sheet		Fair				Balance Sheet	Fair
		Location		Value				Location	Value
	Derivatives designated as hedging instruments:
	Foreign exchange forward contracts	Other current assets		$	21,815			Other current liabilities	$	20,228
	Foreign exchange forward contracts	Other non-current assets		9,839				Other non-current liabilities	14,864
	Total fair value of derivative instruments			$	31,654				$	35,092
Offsetting Assets and Liabilities	'
	The following table summarizes the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts subject to such provisions:
			30-Jun-14
														Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
	Description		Gross Amounts of Recognized Assets/Liabilities				Gross Amounts Offset in the Condensed Consolidated Balance Sheet			Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet				Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
	Derivative assets		$	17,133			$	—		$	17,133			$	(15,934	)	$	—	$	1,199
	Derivative liabilities		(31,014		)		—			(31,014		)		15,934			—		(15,080		)
			December 31, 2013
														Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
	Description		Gross Amounts of Recognized Assets/Liabilities				Gross Amounts Offset in the Condensed Consolidated Balance Sheet			Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet				Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
	Derivative assets		$	31,654			$	—		$	31,654			$	(27,256	)	$	—	$	4,398
	Derivative liabilities		(35,092		)		—			(35,092		)		27,256			—		(7,836		)

Other_Comprehensive_Income_and1

Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Income [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss)	'
	The following tables summarize the changes in AOCI, by component, for the six months ended June 30, 2014 and 2013:
		Defined Benefit Pension Plans				Unrealized Gains (Losses) from Marketable Securities			Unrealized Gains (Losses) from Hedging Activities				Foreign Currency Translation Adjustment				Total Accumulated Other Comprehensive Income (Loss)
	Balances, December 31, 2013	$	(11,502	)		$	(146	)	$	(3,827	)		$	(7,382	)		$	(22,857	)
	Other comprehensive income before reclassifications	(3,086		)		1,111			(8,063		)		552				(9,486		)
	Amounts reclassified from other comprehensive income	401				(1		)	(507		)		—				(107		)
	Net other comprehensive income (loss)	(2,685		)		1,110			(8,570		)		552				(9,593		)
	Balances, June 30, 2014	$	(14,187	)		$	964		$	(12,397	)		$	(6,830	)		$	(32,450	)
		Defined Benefit Pension Plans				Unrealized Gains (Losses) from Marketable Securities			Unrealized Gains (Losses) from Hedging Activities				Foreign Currency Translation Adjustment				Total Accumulated Other Comprehensive Income (Loss)
	Balances, December 31, 2012	$	(5,712	)		$	—		$	15,156			$	(2,809	)		$	6,635
	Other comprehensive income before reclassifications	(2,873		)		(225		)	29,537				(1,529		)		24,910
	Amounts reclassified from other comprehensive income	189				(1		)	(12,207		)		—				(12,019		)
	Net other comprehensive income (loss)	(2,684		)		(226		)	17,330				(1,529		)		12,891
	Balances, June 30, 2013	$	(8,396	)		$	(226	)	$	32,486			$	(4,338	)		$	19,526
Reclassification out of Accumulated Other Comprehensive Income	'
	The table below provides details regarding significant reclassifications from AOCI during the three and six months ended June 30, 2014 and 2013:
	Details about Accumulated Other Comprehensive Income Components		Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended June 30,						Amount Reclassified From Accumulated Other Comprehensive Income during the six months ended June 30,							Affected Line Item in the Condensed Consolidated Statements of Operations
			2014			2013			2014			2013
	Unrealized Gains (Losses) from Hedging Activity
	Effective portion of foreign exchange contracts		$	(695	)	$	7,502		$	571		$	12,655			Net product sales
	Ineffective portion of foreign exchange contracts		187			214			8			686				Foreign currency gain (loss)
			(508		)	7,716			579			13,341
			64			(656		)	(72		)	(1,134		)		Income tax provision
			$	(444	)	$	7,060		$	507		$	12,207
	Unrealized Gains (Losses) from Marketable Securities
	Realized gains (losses) on sale of securities		$	—		$	2		$	2		$	2			Investment income
			—			2			2			2
			—			(1		)	(1		)	(1		)		Income tax provision
			$	—		$	1		$	1		$	1
	Defined Benefit Pension Plans
	Amortization of prior service costs and actuarial losses		$	(359	)	$	(131	)	$	(438	)	$	(207	)		(a)
			(359		)	(131		)	(438		)	(207		)
			31			11			37			18				Income tax provision
			$	(328	)	$	(120	)	$	(401	)	$	(189	)
	(a) This AOCI component is included in the computation of net periodic pension benefit cost (see Note 13 for additional details).

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule Of Assets And Liabilites Measured At Fair Value	'
	The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.
			Fair Value Measurement at
			30-Jun-14
	Balance Sheet	Type of Instrument	Total		Level 1		Level 2		Level 3
	Classification
	Cash equivalents	Institutional money market funds	$	256,300	$	—	$	256,300	$	—
	Marketable securities	Mutual funds	$	2,857	$	2,857	$	—	$	—
	Marketable securities	Commercial paper	$	66,448	$	—	$	66,448	$	—
	Marketable securities	Corporate bonds	$	485,384	$	—	$	485,384	$	—
	Marketable securities	Municipal bonds	$	207,894	$	—	$	207,894	$	—
	Marketable securities	Other government-related obligations	$	201,725	$	—	$	201,725	$	—
	Marketable securities	Bank certificates of deposit	$	18,009	$	—	$	18,009	$	—
	Other current assets	Foreign exchange forward contracts	$	13,018	$	—	$	13,018	$	—
	Other assets	Foreign exchange forward contracts	$	4,115	$	—	$	4,115	$	—
	Other current liabilities	Foreign exchange forward contracts	$	19,729	$	—	$	19,729	$	—
	Other liabilities	Foreign exchange forward contracts	$	11,285	$	—	$	11,285	$	—
	Other current liabilities	Acquisition-related contingent consideration	$	36,395	$	—	$	—	$	36,395
	Contingent consideration	Acquisition-related contingent consideration	$	108,232	$	—	$	—	$	108,232
			Fair Value Measurement at
			31-Dec-13
	Balance Sheet	Type of Instrument	Total		Level 1		Level 2		Level 3
	Classification
	Cash equivalents	Institutional money market funds	$	234,212	$	—	$	234,212	$	—
	Cash equivalents	Commercial paper	$	6,298	$	—	$	6,298	$	—
	Cash equivalents	Corporate bonds	$	15,255	$	—	$	15,255	$	—
	Cash equivalents	Municipal bonds	$	2,225	$	—	$	2,225	$	—
	Cash equivalents	Bank certificates of deposit	$	20,003	$	—	$	20,003	$	—
	Marketable securities	Mutual funds	$	1,017	$	1,017	$	—	$	—
	Marketable securities	Commercial paper	$	106,381	$	—	$	106,381	$	—
	Marketable securities	Corporate bonds	$	461,103	$	—	$	461,103	$	—
	Marketable securities	Municipal bonds	$	200,178	$	—	$	200,178	$	—
	Marketable securities	Other government-related obligations	$	203,313	$	—	$	203,313	$	—
	Marketable securities	Bank certificates of deposit	$	13,001	$	—	$	13,001	$	—
	Other current assets	Foreign exchange forward contracts	$	21,815	$	—	$	21,815	$	—
	Other assets	Foreign exchange forward contracts	$	9,839	$	—	$	9,839	$	—
	Other current liabilities	Foreign exchange forward contracts	$	20,228	$	—	$	20,228	$	—
	Other liabilities	Foreign exchange forward contracts	$	14,864	$	—	$	14,864	$	—
	Other current liabilities	Acquisition-related contingent consideration	$	35,932	$	—	$	—	$	35,932
	Contingent consideration	Acquisition-related contingent consideration	$	106,744	$	—	$	—	$	106,744
Schedule Of Acquisition-Related Contingent Consideration	'
	The following table represents a roll-forward of our acquisition-related contingent consideration:
		Six months ended
		30-Jun-14
	Balance at beginning of period	$	(142,676	)
	Changes in fair value	(1,951		)
	Balance at end of period	$	(144,627	)

Income_Taxes_Tables

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Income Tax Provision and Effective Tax Rate	'
	The following table provides a comparative summary of our income tax provision and effective tax rate for the three and six months ended June 30, 2014 and 2013:
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Provision for income taxes	$	52,151		$	41,378		$	104,708		$	75,902
	Effective tax rate	23.9		%	30.1		%	24.3		%	29.9		%

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
Schedule of Components of Net Periodic Benefit Costs	'
	The components of net periodic benefit cost were as follows:
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Service cost	$	2,622		$	1,326		$	4,185		$	2,711
	Interest cost	200			123			400			249
	Expected return on plan assets	(232		)	(156		)	(463		)	(314		)
	Employee contributions	(482		)	(358		)	(877		)	(713		)
	Amortization	359			131			438			207
	Total net periodic benefit cost	$	2,467		$	1,066		$	3,683		$	2,140

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Inventory, Raw Materials	$16,693	$12,170
Inventory, Work in Process	56,783	62,192
Inventory, Finished Goods	71,383	28,240
Inventory, Net	144,859	102,602
Capitalized Prelaunch Inventory	'	'
Inventory [Line Items]	'	'
Inventory, Net	$9,627	'

Intangible_Assets_and_Goodwill2

Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Licenses, patents and purchased technology	$4,736	$11,205
Acquired in-process research and development	595,050	598,514
Intangible assets	599,786	609,719
Goodwill	$254,073	$254,073

Intangible_Assets_and_Goodwill3

Intangible Assets and Goodwill (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$0	$0	$3,464	$0

Debt_Details

Debt (Details) (Credit Agreement [Member], USD $)	0 Months Ended
In Thousands, unless otherwise specified	Feb. 07, 2012	Jun. 30, 2014
Senior Secured Term Loan [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt instrument, principal amount	$240,000	'
Debt Instrument, Periodic Payment	12,000	'
Outstanding debt	'	81,500
Line of Credit [Member]	'	'
Debt Instrument [Line Items]	'	'
Line of credit facility, maximum borrowing capacity	200,000	'
Possible future increase in credit facility	150,000	'
Letters of credit, amount outstanding	'	12,445
Line of credit facility, borrowing availability	'	187,555
Letter of Credit [Member]	'	'
Debt Instrument [Line Items]	'	'
Sublimit for letter of credit for working capital requirements and other general corporate purposes	60,000	'
Bridge Loan [Member]	'	'
Debt Instrument [Line Items]	'	'
Sublimit for letter of credit for working capital requirements and other general corporate purposes	$10,000	'

Earnings_Per_Common_Share_Summ

Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Common Share [Abstract]	'	'	'	'
Net income used for basic and diluted calculation	$166,495	$95,885	$325,849	$178,102
Shares used in computing earnings per common sharebbasic	197,880	195,247	197,838	193,944
Stock awards	3,644	4,052	3,877	4,152
Dilutive potential common shares	3,644	4,052	3,877	4,152
Shares used in computing earnings per common share-diluted	201,524	199,299	201,715	198,096
Earnings Per Share, Basic	$0.84	$0.49	$1.65	$0.92
Earnings Per Share, Diluted	$0.83	$0.48	$1.62	$0.90

Earnings_Per_Common_Share_Narr

Earnings Per Common Share (Narrative) (Details)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,698	2,265	1,151	3,037

Marketable_Securities_Summary_

Marketable Securities (Summary of Securities Held) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$978,225	$1,027,978
Gross Unrealized Holding Gains	1,417	618
Gross Unrealized Holding Losses	-182	-839
Estimated Fair Value	979,460	1,027,757
Commercial Paper [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	66,448	112,679
Gross Unrealized Holding Gains	0	0
Gross Unrealized Holding Losses	0	0
Estimated Fair Value	66,448	112,679
Corporate Bond Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	484,588	476,459
Gross Unrealized Holding Gains	916	487
Gross Unrealized Holding Losses	-120	-588
Estimated Fair Value	485,384	476,358
Municipal Bonds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	207,643	202,396
Gross Unrealized Holding Gains	251	47
Gross Unrealized Holding Losses	0	-40
Estimated Fair Value	207,894	202,403
US Government Agencies Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	51,969	46,466
Gross Unrealized Holding Gains	37	30
Gross Unrealized Holding Losses	-21	-7
Estimated Fair Value	51,985	46,489
Foreign Government Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	149,573	156,974
Gross Unrealized Holding Gains	208	54
Gross Unrealized Holding Losses	-41	-204
Estimated Fair Value	149,740	156,824
Certificates of Deposit [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	18,004	33,004
Gross Unrealized Holding Gains	5	0
Gross Unrealized Holding Losses	0	0
Estimated Fair Value	$18,009	$33,004

Marketable_Securities_Availabl

Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities	$979,460	$1,027,757
Cash and Cash Equivalents [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities	0	43,780
Marketable Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities	$979,460	$983,977

Marketable_Securities_Availabl1

Marketable Securities (Available-for-sale Debt Securities by Contractual Maturity) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Investments, Debt and Equity Securities [Abstract]	'	'
Due in one year or less	$417,471	'
Due after one year through three years	561,989	'
Due after three years through five years	0	'
Estimated Fair Value	$979,460	$1,027,757

Marketable_Securities_Narrativ

Marketable Securities (Narrative) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Investments, Debt and Equity Securities [Abstract]	'	'
Aggregate fair value of investments in continuous unrealized loss position	$210,079	$461,634
Trading securities. fair value	$2,857	$1,017

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Activities (Narrative) (Details) (USD $)	6 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
	Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]	Foreign Exchange Forward [Member]	Foreign Exchange Forward [Member]	Foreign Exchange Forward [Member]
						Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]
Derivative [Line Items]	'	'	'	'	'	'	'	'
Foreign Exchange Forward Contracts Term	'36 months	'	'	'30 days	'	'	'	'
Notional Amount of Derivative Instruments	'	'	'	'	'	$1,410,389,000	$239,318,000	'
Estimated gains (losses) to be reclassified from other comprehenisve income in next 12 months	-7,000,000	'	'	'	'	'	'	'
Gain (loss) in other income and expense	'	-1,640,000	1,837,000	649,000	8,787,000	'	'	'
Derivative, fair value, net	'	'	'	'	'	'	$0	$0

Derivative_Instruments_and_Hed3

Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Derivative Instruments and Hedging Activities [Abstract]	'	'	'	'
Gain (loss) recognized in AOCI, net of tax	($4,119)	($1,388)	($8,063)	$29,537
Gain (loss) reclassified from AOCI to net product sales (Effective portion), net of tax	-608	6,864	500	11,579
Gain (loss) reclassified from AOCI to other income and expense (Ineffective portion), net of tax	$164	$196	$7	$628

Derivative_Instruments_and_Hed4

Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) (Foreign Exchange Forward [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Asset Derivatives, Fair Value	$17,133	$31,654
Liability Derivatives, Fair Value	31,014	35,092
Other Current Assets [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Asset Derivatives, Fair Value	13,018	21,815
Other Current Liabilities [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Liability Derivatives, Fair Value	19,729	20,228
Other Noncurrent Assets [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Asset Derivatives, Fair Value	4,115	9,839
Other Noncurrent Liabilities [Member] | Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Liability Derivatives, Fair Value	$11,285	$14,864

Derivative_Instruments_and_Hed5

Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details) (Foreign Exchange Forward [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Foreign Exchange Forward [Member]	'	'
Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract]	'	'
Gross Amounts of Recognized Assets	$17,133	$31,654
Gross Amounts Offset in the Condensed Consolidated Balance Sheet	0	0
Amounts of Assets Presented in the Condensed Consolidated Balance Sheet	17,133	31,654
Derivative Financial Instruments	-15,934	-27,256
Cash Collateral Received	0	0
Net Amount	1,199	4,398
Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract]	'	'
Gross Amounts of Recognized Liabilities	-31,014	-35,092
Gross Amounts Offset in the Condensed Consolidated Balance Sheet	0	0
Amounts of Liabilities Presented in the Condensed Consolidated Balance Sheet	-31,014	-35,092
Derivative Financial Instruments	15,934	27,256
Cash Collateral Pledged	0	0
Net Amount	($15,080)	($7,836)

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended	6 Months Ended	1 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Nov. 30, 2012	Jun. 30, 2014	Jul. 25, 2014
					Common Stock [Member]	Common Stock [Member]	Subsequent Event [Member]
Class of Stock [Line Items]	'	'	'	'	'	'	'
Stock Repurchase Program, Authorized Amount	'	'	'	'	$400,000	'	'
Treasury Stock, Shares, Acquired	1,012	353	1,149	758	'	'	180
Treasury Stock, Value, Acquired, Cost Method	156,458	31,029	178,515	66,136	'	'	28,968
Stock Repurchase Program, Remaining Authorized Repurchase Amount	'	'	'	'	'	$143,796	'

Other_Comprehensive_Income_and2

Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning balance	'	'	($22,857)	$6,635
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	'	'	-9,486	24,910
Amounts reclassified from other comprehensive income	'	'	-107	-12,019
Other comprehensive loss, net of tax	-6,015	-11,435	-9,593	12,891
Ending balance	-32,450	19,526	-32,450	19,526
Accumulated Defined Benefit Plans Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning balance	'	'	-11,502	-5,712
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	'	'	-3,086	-2,873
Amounts reclassified from other comprehensive income	'	'	401	189
Other comprehensive loss, net of tax	'	'	-2,685	-2,684
Ending balance	-14,187	-8,396	-14,187	-8,396
Accumulated Net Unrealized Investment Gain (Loss) [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning balance	'	'	-146	0
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	'	'	1,111	-225
Amounts reclassified from other comprehensive income	'	'	-1	-1
Other comprehensive loss, net of tax	'	'	1,110	-226
Ending balance	964	-226	964	-226
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning balance	'	'	-3,827	15,156
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	'	'	-8,063	29,537
Amounts reclassified from other comprehensive income	'	'	-507	-12,207
Other comprehensive loss, net of tax	'	'	-8,570	17,330
Ending balance	-12,397	32,486	-12,397	32,486
Accumulated Translation Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning balance	'	'	-7,382	-2,809
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	'	'	552	-1,529
Amounts reclassified from other comprehensive income	'	'	0	0
Other comprehensive loss, net of tax	'	'	552	-1,529
Ending balance	($6,830)	($4,338)	($6,830)	($4,338)

Other_Comprehensive_Income_and3

Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details) (USD $)	3 Months Ended				6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Reclassification out of Accumulated Other Comprehensive Income [Line Items]	'		'		'		'
Net product sales	$512,495		$370,091		$1,079,111		$709,032
Foreign currency gain (loss)	-1,202		-90		56		413
Investment income	1,714		718		3,927		1,155
Income before income taxes	218,646		137,263		430,557		254,004
Income tax provision	-52,151		-41,378		-104,708		-75,902
Net income	166,495		95,885		325,849		178,102
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]	'		'		'		'
Reclassification out of Accumulated Other Comprehensive Income [Line Items]	'		'		'		'
Net product sales	-695		7,502		571		12,655
Foreign currency gain (loss)	187		214		8		686
Income before income taxes	-508		7,716		579		13,341
Income tax provision	64		-656		-72		-1,134
Net income	-444		7,060		507		12,207
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]	'		'		'		'
Reclassification out of Accumulated Other Comprehensive Income [Line Items]	'		'		'		'
Investment income	0		2		2		2
Income before income taxes	0		2		2		2
Income tax provision	0		-1		-1		-1
Net income	0		1		1		1
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]	'		'		'		'
Reclassification out of Accumulated Other Comprehensive Income [Line Items]	'		'		'		'
Amortization of prior service costs and actuarial losses	-359	[1]	-131	[1]	-438	[1]	-207	[1]
Income before income taxes	-359		-131		-438		-207
Income tax provision	31		11		37		18
Net income	($328)		($120)		($401)		($189)
[1]	This AOCI component is included in the computation of net periodic pension benefit cost (see Note 13 for additional details).

Fair_Value_Measurement_Schedul

Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Foreign Exchange Forward [Member] | Other Current Liabilities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, liability	$19,729	$20,228
Foreign Exchange Forward [Member] | Other Current Liabilities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, liability	0	0
Foreign Exchange Forward [Member] | Other Current Liabilities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, liability	19,729	20,228
Foreign Exchange Forward [Member] | Other Current Liabilities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, liability	0	0
Foreign Exchange Forward [Member] | Other Noncurrent Liabilities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, liability	11,285	14,864
Foreign Exchange Forward [Member] | Other Noncurrent Liabilities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, liability	0	0
Foreign Exchange Forward [Member] | Other Noncurrent Liabilities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, liability	11,285	14,864
Foreign Exchange Forward [Member] | Other Noncurrent Liabilities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, liability	0	0
Acquisition Related Contingent Consideration [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business Combination, Contingent Consideration, Liability	144,627	'
Acquisition Related Contingent Consideration [Member] | Other Current Liabilities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business Combination, Contingent Consideration, Liability	36,395	35,932
Acquisition Related Contingent Consideration [Member] | Other Current Liabilities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business Combination, Contingent Consideration, Liability	0	0
Acquisition Related Contingent Consideration [Member] | Other Current Liabilities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business Combination, Contingent Consideration, Liability	0	0
Acquisition Related Contingent Consideration [Member] | Other Current Liabilities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business Combination, Contingent Consideration, Liability	36,395	35,932
Acquisition Related Contingent Consideration [Member] | Contingent Consideration [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business Combination, Contingent Consideration, Liability	108,232	106,744
Acquisition Related Contingent Consideration [Member] | Contingent Consideration [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business Combination, Contingent Consideration, Liability	0	0
Acquisition Related Contingent Consideration [Member] | Contingent Consideration [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business Combination, Contingent Consideration, Liability	0	0
Acquisition Related Contingent Consideration [Member] | Contingent Consideration [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business Combination, Contingent Consideration, Liability	108,232	106,744
Money Market Funds [Member] | Cash Equivalents [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	256,300	234,212
Money Market Funds [Member] | Cash Equivalents [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	0	0
Money Market Funds [Member] | Cash Equivalents [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	256,300	234,212
Money Market Funds [Member] | Cash Equivalents [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	0	0
Mutual Funds [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	2,857	1,017
Mutual Funds [Member] | Marketable Securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	2,857	1,017
Mutual Funds [Member] | Marketable Securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Mutual Funds [Member] | Marketable Securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Commercial Paper [Member] | Cash Equivalents [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	6,298
Commercial Paper [Member] | Cash Equivalents [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	0
Commercial Paper [Member] | Cash Equivalents [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	6,298
Commercial Paper [Member] | Cash Equivalents [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	0
Commercial Paper [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	66,448	106,381
Commercial Paper [Member] | Marketable Securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Commercial Paper [Member] | Marketable Securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	66,448	106,381
Commercial Paper [Member] | Marketable Securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Corporate Bond Securities [Member] | Cash Equivalents [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	15,255
Corporate Bond Securities [Member] | Cash Equivalents [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	0
Corporate Bond Securities [Member] | Cash Equivalents [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	15,255
Corporate Bond Securities [Member] | Cash Equivalents [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	0
Corporate Bond Securities [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	485,384	461,103
Corporate Bond Securities [Member] | Marketable Securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Corporate Bond Securities [Member] | Marketable Securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	485,384	461,103
Corporate Bond Securities [Member] | Marketable Securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Municipal Bonds [Member] | Cash Equivalents [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	2,225
Municipal Bonds [Member] | Cash Equivalents [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	0
Municipal Bonds [Member] | Cash Equivalents [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	2,225
Municipal Bonds [Member] | Cash Equivalents [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	0
Municipal Bonds [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	207,894	200,178
Municipal Bonds [Member] | Marketable Securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Municipal Bonds [Member] | Marketable Securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	207,894	200,178
Municipal Bonds [Member] | Marketable Securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Other Government Obligations [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	201,725	203,313
Other Government Obligations [Member] | Marketable Securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Other Government Obligations [Member] | Marketable Securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	201,725	203,313
Other Government Obligations [Member] | Marketable Securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Certificates of Deposit [Member] | Cash Equivalents [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	20,003
Certificates of Deposit [Member] | Cash Equivalents [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	0
Certificates of Deposit [Member] | Cash Equivalents [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	20,003
Certificates of Deposit [Member] | Cash Equivalents [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	'	0
Certificates of Deposit [Member] | Marketable Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	18,009	13,001
Certificates of Deposit [Member] | Marketable Securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Certificates of Deposit [Member] | Marketable Securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	18,009	13,001
Certificates of Deposit [Member] | Marketable Securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Marketable securities	0	0
Foreign Exchange Forward [Member] | Other Current Assets [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, asset	13,018	21,815
Foreign Exchange Forward [Member] | Other Current Assets [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, asset	0	0
Foreign Exchange Forward [Member] | Other Current Assets [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, asset	13,018	21,815
Foreign Exchange Forward [Member] | Other Current Assets [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, asset	0	0
Foreign Exchange Forward [Member] | Other Noncurrent Assets [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, asset	4,115	9,839
Foreign Exchange Forward [Member] | Other Noncurrent Assets [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, asset	0	0
Foreign Exchange Forward [Member] | Other Noncurrent Assets [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, asset	4,115	9,839
Foreign Exchange Forward [Member] | Other Noncurrent Assets [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign exchange forward contracts, asset	$0	$0

Fair_Value_Measurement_Schedul1

Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low	$0
Business Combination, Contingent Consideration, Arrangements, Range of Outcomes, Value, High	876,000
Acquisition Related Contingent Consideration [Member]	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'
Business Combination, Contingent Consideration, Liability	144,627
Acquisition Related Contingent Consideration [Member] | Level 3 [Member]	'
Acquisition-Related Contingent Consideration [Roll Forward]	'
Balance at beginning of period	-142,676
Change in fair value	-1,951
Balance at end of period	($144,627)
Acquisition Related Contingent Consideration [Member] | Minimum [Member] | Level 3 [Member]	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'
Fair Value Inputs, Cost of Debt	5.30%
Fair Value Inputs, Weighted Average Cost of Capital	14.00%
Acquisition Related Contingent Consideration [Member] | Maximum [Member] | Level 3 [Member]	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'
Fair Value Inputs, Cost of Debt	6.20%
Fair Value Inputs, Weighted Average Cost of Capital	21.00%

Income_Taxes_Schedule_of_Incom

Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Provision for income taxes	$52,151	$41,378	$104,708	$75,902
Effective tax rate	23.90%	30.10%	24.30%	29.90%

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
		Internal Revenue Service (IRS) [Member]
Income Taxes [Line Items]	'	'
Foreign Income Tax Expense (Benefit), Continuing Operations	$2,128	'
Income Tax Reconciliation, Tax Credits, Research	'	$3,033

Employee_Benefit_Plans_Narrati

Employee Benefit Plans (Narrative) (Details) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended
	Jun. 15, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'	'	'	'	'	'
Voluntary deferrals, percent of employees' gross pay, maximum	80.00%	'	'	'	'	'
Deferred compensation, matching contribution, percent of match	6.00%	'	'	'	'	'
Deferred compensation liability	'	$2,857,000	'	$2,857,000	'	$1,097,000
Amount of each dollar matching contributed up to first six percent of individual base salary and incentive cash bonus	'	'	'	1	'	'
Percentage of contribution of individual's base salary and incentive cash bonus	'	'	'	6.00%	'	'
Defined contribution plan, contributions by employer	'	$2,279,000	$1,497,000	$4,936,000	$3,264,000	'

Employee_Benefit_Plans_Schedul

Employee Benefit Plans (Schedule of Components of Net Periodic Benefit Cost) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Compensation and Retirement Disclosure [Abstract]	'	'	'	'
Service cost	$2,622	$1,326	$4,185	$2,711
Interest cost	200	123	400	249
Expected return on plan assets	-232	-156	-463	-314
Employee contributions	-482	-358	-877	-713
Amortization	359	131	438	207
Total net periodic benefit cost	$2,467	$1,066	$3,683	$2,140

Leases_Details

Leases (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Operating Leased Assets [Line Items]	'	'
Facility Lease Obligation, Noncurrent	$59,515	$32,230
Construction in Progress [Member]	'	'
Operating Leased Assets [Line Items]	'	'
Construction-in-process asset	$62,157	'

License_Agreements_Details

License Agreements (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
	target
Option to Purchase Drug Product [Member]	'
Schedule of License Agreements [Line Items]	'
Research and Development Arrangement, Number of Targets	10
Research and Development Expense (Excluding Acquired in Process Cost)	$100,000
Research and Development Arrangement, Potential Option Exercise Payment	15,000
Rare Disease Products [Member] | Option to Purchase Drug Product [Member]	'
Schedule of License Agreements [Line Items]	'
Research and Development Arrangement, Potential Payment, Maximum	120,000
Non-Rare Disease Product [Member] | Option to Purchase Drug Product [Member]	'
Schedule of License Agreements [Line Items]	'
Research and Development Arrangement, Potential Payment, Maximum	400,000
Preferred Stock [Member] | Moderna LLC [Member]	'
Schedule of License Agreements [Line Items]	'
Payments to Acquire Investments	$25,000

Commitments_and_Contingencies_

Commitments and Contingencies (Narrative) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified		Cost of Sales
Other Commitments [Line Items]	'	'
Remaining total commitments with Lonza	$146,000	'
Inventory recall expense	'	$14,277